01357nas a2200409   4500000000100000000000100001008004100002653001100043653007700054653004400131653000900175653001100184653004700195653007300242653001600315653000900331653003100340653001400371653005700385653003200442653001900474653004600493100002200539700001400561700001100575700001000586700001000596700001500606700001400621700001400635700001500649245021600664250001500880300001200895490000800907020003200915       2024                            d10aHumans10a*Sodium-Glucose Transporter 2 Inhibitors/therapeutic use/adverse effects10a*Diabetes Mellitus, Type 2/drug therapy10aMale10aFemale10a*Glucagon-Like Peptide-1 Receptor/agonists10a*Cardiovascular Diseases/prevention & control/epidemiology/mortality10aMiddle Aged10aAged10a*Drug Therapy, Combination10aIncidence10a*Hypoglycemic Agents/therapeutic use/adverse effects10aUnited Kingdom/epidemiology10aCohort Studies10aGlucagon-like peptide-1 receptor agonists1 aN. Simms-Williams1 aN. Treves1 aH. Yin1 aS. Lu1 aO. Yu1 aR. Pradhan1 aC. Renoux1 aS. Suissa1 aL. Azoulay00aEffect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study  a2024/04/26  ae0782420 v385  a0959-8138 (Print)
0959-8138